Circassia Pharmaceuticals (CIR)
Circassia develops short-course allergy therapies and a range of asthma treatments. It has a broad range of treatments in development, with many in late-stage clinical studies.
The most advanced allergy therapy is currently undergoing phase III testing, and their asthma treatment is undergoing regulatory review.
Circassia regularly publishes its scientific progress in peer-reviewed journals, and presents results at leading scientific conferences.
- Pharmaceuticals & Biotechnology
- 🇬🇧 United Kingdom
- £0.64 Friday's close
52 Week High0.0%07 December 2018
52 Week Low0.0%07 December 2018
Next Ex-Div-Date Countdown
|Ex-Div Date||Pay Date||Year||Type||Frequency||Status||Amount|
Circassia Pharmaceuticals optimized dividend - 12 month history
Circassia Pharmaceuticals share price - 12 month history
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn: